- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- News News
- Join Join
Contact: Sean Khalepari | [email protected]
Washington, DC — On May 31, 2019 the FDA will be holding a public hearing to collect scientific information and data on cannabis and cannabis derived products. In holding this hearing, the FDA is seeking public input on topics including health & safety risks, manufacturing & product quality, and marketing, labeling and sales. The FDA hearing on Products Containing Cannabis or Cannabis-Derived Compounds is scheduled from 7:00 AM - 6:00 PM.
The FDA received almost 400 requests to present and/or provide oral remarks at the hearing. Americans for Safe Access was one of seventy-two organizations selected to give a formal presentation, and one of only fifty-two organizations selected to give a full five minute presentation with slides.
“With only five minutes to present information to the FDA, we are limited in what we can accomplish in such a short time frame” said Heather Despres, M. Sc., Director of Patient Focused Certification. “However, with the submission of our written comments and our in-person testimony, we can show the FDA not only the scientific information they are looking for but also provide solutions to problems and give patients the voice they deserve.”
The Agriculture Improvement Act of 2018 (also known as the 2018 Farm Bill) legalized industrial hemp (cannabis plants containing not more than 0.3% THC), which has sparked even further interest in CBD products. Some estimates indicate that the legal CBD industry will generate more than than $22 billion dollars by 2022. Many have turned to CBD products to assist with general wellness or to improve specific health conditions. In response to this, ASA will be releasing their Patient’s Guide to CBD next week.
As of May 30, 827 comments have been submitted to the FDA through the agency’s online portal. The comment period closes on July 2. This public hearing is likely to be the first of many as the FDA promulgates rules for cannabis products.